Cyclobutyl nucleoside analogues containing guanine and 8-azaguanine (compounds 5-10) were prepared from (1R,cis)-3-aminomethyl-2,2-dimethylcyclobutylmethanol (1). All were evaluated as antiviral and antitumoral agents in a variety of assay systems. Compounds 6 and 7 showed a noteworthy activity against a respiratory syncytial virus and compound 10 was moderately active against vaccinia virus. Only compound 5 showed some cytostatic activity.
Because of their crucial roles in the storage and transfer of metabolic energy and genetic information, nucleosides are among the most important of biomolecules. This has stimulated great interest in nucleoside analogues as potential antiviral and antineoplastic agents. [1] [2] [3] One of the example is oxetanocin A (I), a natural antibiotic that is derived from oxetane and which, following conversion to its 5-triphosphate, is a potent inhibitor of human inmunodeficiency virus (HIV-1) reverse transcriptase and is thus of potential value for the treatment of AIDS; 4) its carbocyclic analogue, cyclobut-G (II), 5) is not only active against HIV but also against herpes simplex virus (HSV-1 and HSV-2), cytomegalovirus 6, 7) and hepatitis B virus. 8) As yet there are no general rules relating the structures of carbocyclic nucleosides to their therapeutic activity, although trends among certain kinds of structure have been tentatively put forward. 9) Among the structural characteristics to be considered are conformational mobility, the distance separating the hydroxymethyl oxygen and pseudo-glycosidic nitrogen, the presence of lipophilic groups, and the absolute and relative configurations of these molecules. 10) In this work we synthesized a variety of dimethylcyclobutyl carbonucleosides, which are related to other 9-[cis-3-(hydroxymethyl)cyclobutyl]purines, 11) starting from enantiomerically pure aminoalcohol 1. 12) Our analogues differ from cyclobut-G itself in that they have the opposite absolute configurations at their stereogenic centers, bear a gem-dimethyl group instead of hydroxymethyl group at C2, and have an extra methylene group between the carbocycle and the heterocyclic moieties.
Their synthesis is detailed in Chart 1; in all cases, the guanine or modified guanine base was constructed 13) on the amino group of the precursor (1R,cis)-3-aminomethyl-2,2-dimethylcyclobutylmethanol (1).
Briefly, 1 was condensed with 2-amino-4,6-dichloropyrimidine (72% yield), the resulting pyrimidinylamino compound 2 was reacted with 4-chlorobenzenediazonium chloride to afford the 5-(4-chlorophenylazo)pyrimidine 3 (87% yield), and this latter was reduced with Zn in acetic acid to give the triaminopyrimidine 4 (63% yield). Compound 4 was then cyclized, either with triethyl orthoformate, which gave (1R,cis)-3-(2-amino-6-chloro-9H-purin-9-ylmethyl)-2,2-dimethylcyclobutylmethanol (5) in 92% yield, or with sodium nitrite in acetic acid, which gave (1R,cis)- (8) in 85% yield. The guanosine analogue 6 was obtained by hydrolysis of 5 in dilute sodium hydroxide (73% yield), and the 2,6-diaminopurinyl compound 7 was obtained by amination of 5 in aqueous ammonia (54% yield). Compound 8 was converted to 9 by treating it with sodium hydroxide (70% yield), and to the corresponding 8-azaguanosine analogue 10 by treatment with aqueous ammonia (83% yield).
The antiviral activities of compounds 5-10 were determined in vitro against a variety of viruses using previously established procedures. 14 Though all the new compounds showed no detectable activity in most of the tests performed, it is noteworthy that compounds 6 and 7 showed activity against respiratory syncytial virus, with MIC 50 values of 6 and 4 mg/ml respectively, (at 66 to 100 times below the cytotoxic concentration for the host cells). Compound 10 was also active against vaccinia virus, with an MIC 50 value of 50 mg/ml (8 times below the cytotoxic concentration). Compound 5, which showed moderate activity against Coxsackie B4 virus (MIC 50 of 150 mg/ml), was the most active of our compounds in the cytostatic tests, with IC 50 values of 111, 81 and 64 mg/ml against L1210/0, CEM/0 and Molt4/C8, respectively.
Experimental
Melting points were determined on a Reichert Kofler thermopan and are uncorrected. Sodium-D line polarimetry was carried out in a Perkin-Elmer 241 polarimeter. IR spectra of the samples in KBr discs (solids) or as films between NaCl plates (oils) were recorded in a Perkin-Elmer FTIR 1640 spectrometer. 1 H and 13 C-NMR spectra were recorded in a Bruker AMX-300 spectrometer, at 300 and 75 MHz, respectively, with tetramethylsilane (TMS) as an internal standard. Microanalyses were done at the Microanalysis Service, University of Santiago, using a Perkin-Elmer 240B Elemental Analyzer. Silica gel (400 mesh) for flash chromatography (FC) was from Merck. Reagents and solvents were of commercial grade (Aldrich Chemical Co.).
(؉)-(1R,cis)-3-(2-Amino-6-chloropyrimidin-4-ylaminomethyl)-2,2-dimethylcyclobutylmethanol (2) A solution of 1 (5.25 g, 36.7 mmol), 2-amino-4,6-dichloropyrimidine (9.20 g, 56.1 mmol) and triethylamine (22 ml) in dry 1-butanol (93 ml) was refluxed under a dry atmosphere for 48 h, whereafter the reaction mixture was cooled and the solvent was removed in vacuo. The residue was purified by FC (eluent CH 2 Cl 2 /MeOH 1 : 1), then redissolved in dry acetone. The solution was filtered and the solvent was evaporated in vacuo to afford compound 2 as a colorless foam (7.21 g, 72% (
؉)-(1R,cis)-3-[(2-Amino-6-chloro-5-(4-chlorophenylazo)pyrimidin-4-ylaminomethyl]-2,2-dimethylcyclobutylmethanol (3)
4-Chloroaniline (3.80 g, 30.8 mmol) in 3 N HCl (27 ml) was treated at 0°C with NaNO 2 (2.25 g, 32.6 mmol) in water (25 ml). The diazonium salt obtained was added to a mixture of 2 (6.98 g, 25.8 mmol), NaOAc · 3H 2 O (51.2 g), acetic acid (128 ml) and water (128 ml) and stirred overnight at room temperature. The precipitate was filtered out, washed with water until the washings were neutral, and dried to afford 3 (9.17 g, 87%) as a yellow solid. ؉)-(1R,cis)-3-(2,5-Diamino-6-chloropyrimidin-4-ylaminomethyl)-2,2 (
؉)-(1R,cis)-3-(2-Amino-6-chloro-9H-purin-9-ylmethyl)-2,2-dimethylcyclobutylmethanol (5)
A mixture of 4 (1.80 g, 6.30 mmol), triethyl orthoformate (25 ml) and 12 N HCl (1.6 ml) under argon was stirred overnight at room temperature. The mixture was concentrated to dryness in vacuo, and 0.5 N HCl (30 ml) was added to the residue and stirred for 1 h. Then, the reaction mixture was adjusted to pH 8 with 1 N NaOH, and the solvent was evaporated in vacuo. The crude product was purified by FC (eluent EtOAc). (
؉)-(1R,cis)-3-(2-Amino-1,6-dihydro-6-oxo-9H-purin-9-ylmethyl)-2,2-dimethylcyclobutylmethanol (6)
A mixture of 5 (0.60 g, 2.03 mmol) and 0.33 N NaOH (48 ml) was refluxed for 6 h, whereupon the solvent was removed in vacuo. The residue was purified by FC (eluent EtOAc) to afford compound 6 (0.41 g, 73%) as a white solid. An analytical sample was obtained by recrystallization of the crude product from EtOH, mp 258-260°C, [ (؉)-(1R,cis)-3-(2,6-Diamino-9H-purin-9-ylmethyl)-2,2-dimethylcyclobutylmethanol (7) A suspension of 5 (0.50 g, 1.68 mmol) in concentrated NH 4 OH (50 ml) was heated under reflux for 1 h. The reaction mixture was concentrated in vacuo to a yellow solid (0.60 g), which was purified by FC (eluent EtOAc/MeOH 7 : 3) to afford compound 7 (0.25 g, 54%) as a white solid. (؊)-(1R,cis)-3-(5-Amino-7-chloro-3H-[1,2,3]triazolo[4,5-d ] pyrimidin-3-ylmethyl)-2,2-dimethylcyclobutylmethanol (8) Sodium nitrite (0.43 g, 6.27 mmol) in water (13 ml) was added to a cooled (0°C) solution of 4 (1.45 g, 5.10 mmol) in acetic acid (8 ml) and water (13 ml), then stirred for 3 h. After work-up, an oil (2.5 g) was obtained, which was purified by FC (eluent EtOAc) to afford compound 8 as a white solid (1.28 g, 85% Biological Activity Assays The methods used to assess antiviral activity and cytotoxicity have been described previously. 14, 15) 
